Alzheimer's disease genetic biomarker determination method and system

Abstract

The invention discloses an Alzheimer's disease genetic biomarker determination method and system. The Alzheimer's disease genetic biomarker determination method comprises the steps: obtaining magneticresonance imaging data of Alzheimer's disease, and carrying out data expansion processing on the magnetic resonance imaging data; performing two-dimensional slicing on the magnetic resonance imagingdata, and training a preset convolutional neural network by the two-dimensional slicing to obtain a plurality of base classifiers; screening the base classifier, and positioning a feature brain regionof the Alzheimer's disease by combining the base classifier obtained by screening and the brain map; extracting characteristic brain area volume data from the magnetic resonance imaging data; obtaining gene data of the Alzheimer's disease, and obtaining potential genetic biomarkers of the Alzheimer's disease after the gene data and characteristic brain area volume data are subjected to whole genome correlation analysis. The invention provides a new research method and path for early diagnosis of Alzheimer's disease, and can be widely applied to other computer-aided diagnosis fields.

Description

technical field [0001] The invention relates to the field of computer-aided diagnosis, in particular to a method and system for determining genetic biomarkers of Alzheimer's disease. Background technique [0002] Alzheimer's Disease (AD) is a typical neurodegenerative disease, clinically manifested as amnesia, loss of language ability, and loss of self-care ability. With the acceleration of population aging in modern society, the number of patients with this disease is increasing rapidly, which brings great pain and burden to patients and their families. So far, the cause of the disease is not clear and the course of the disease is irreversible, and there is no cure for the disease. Therefore, early diagnosis of AD is of great significance for the development of new drugs and measures to slow down the progression of the disease. Mild cognitive impairment (Mild Cognitive Impairment, MCI) is a state between AD and healthy state HC (Healthy Controls, HC), can be subdivided in...

AI Technical Summary

Problems solved by technology

However, since the current early AD diagnosis methods based on machine learning often require manual extraction of image features, the selected regions of interest rely on prior knowledge such as existing AD neuroimaging biomarkers, which has limitations.

At the same time, manual extraction of features requires a lot of manpower and time, and manual operation will also increase the uncertainty of the experiment

But there is currently no technology that can identify genetic biomarkers for Alzheimer's disease

Images